Corbus Pharmaceuticals Announces Addition of Phase 2

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Corbus Pharmaceuticals Announces Addition of Phase 2 Clinical Protocol for Resunab Treatment of Systemic Lupus Erythematosus to FDA IND

NORWOOD, MA --(Marketwired - March 31, 2016) - Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ : CRBP ) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that a protocol amendment has been added to one of the Company's existing Investigational New Drug ("IND") Application with the U.S. Food and Drug Administration ("FDA") for a Phase 2 clinical trial of Resunab in systemic lupus erythematosus ("SLE"). The amendment was filed on February 25, 2016. The addition of the SLE Phase 2 trial to the existing Resunab IND is an important step towards the initiation of the 100 patient, double-blind, placebo-controlled SLE trial which will be funded by a grant from the National Institutes of Health ("NIH") to the Feinstein Institute for Medical Research ("FIMR"), Manhasset. The Company expects the trial will commence in the first quarter of 2017.

Resunab is a novel synthetic endocannabinoid-mimetic drug that we believe has the potential to resolve widespread inflammation associated with active SLE, and, in particular, inflammation of the musculoskeletal system. The Phase 2 SLE trial will evaluate Resunab at 5 mg, 20 mg, and 20 mg twice daily, administered orally for 84 days, with 28 days follow-up, at approximately ten U.S. sites. The primary outcome assesses pain from active musculoskeletal disease and secondary efficacy outcomes include assessments of overall disease activity using standard SLE Disease Activity Index ("SLEDAI") and British Isles Lupus Activity Group ("BILAG") scoring systems in SLE. Resunab is currently being evaluated in three on-going Phase 2 clinical trials for the treatment of cystic fibrosis, systemic sclerosis, and dermatomyositis

"The support from the NIH's Autoimmunity Centers of Excellence to FIMR and Meggan Mackay, M.D., M.S., Principal investigator in this Phase 2 trial, is invaluable to the expansion of the clinical testing of Resunab into another serious autoimmune disease," stated Barbara White, M.D., Chief Medical Officer of Corbus. "Resunab has a novel mechanism of action and is designed to trigger endogenous pathways to turn off chronic inflammation and fibrotic processes, without causing immunosuppression. Based on the existing clinical safety data and the pre-clinical efficacy data, we see an opportunity for Resunab to provide therapeutic benefits to individuals living with SLE."

Dr. Mackay added, "Corticosteroids or other immunosuppressive therapies are commonly used by physicians to treat patients with SLE who have active musculoskeletal disease that is refractory to anti-malarial agents and NSAIDS. Because these treatments can have major toxicities, there remains a significant unmet medical need in the treatment of SLE. I believe Resunab has the potential to treat active musculoskeletal disease and overall disease activity in SLE."

About Systemic Lupus Erythematosus

Systemic lupus erythematosus is a prototypical autoimmune disease in which the innate immune system is chronically activated by immune complexes containing autoantibodies and self-antigens, which leads to widespread inflammation and tissue damage. SLE typically occurs more often in women than men and is most common between the ages 15 to 35. According to the CDC, SLE affects between 161,000 - 322,000 people in the United States and about 500,000 people worldwide. SLE has many manifestations, including arthritis, rash, photosensitivity, oral ulcers, pleuritis, pericarditis, kidney problems, seizures and psychosis and blood cell abnormalities. The musculoskeletal system is the most commonly involved system in SLE. The pathology of SLE involves chronic activation of the innate immune system by immune complexes, with activation of complement, increased production of type 1 interferons and other mediators of inflammation and resultant tissue inflammation and damage. Patients with SLE have an increased frequency of related autoimmune problems, such as Sjogren's syndrome and antiphospholipid syndrome that require additional treatments. SLE may occur with other autoimmune conditions, such as thyroiditis, hemolytic anemia, and idiopathic thrombocytopenia purpura. Accelerated atherosclerosis among SLE patients is responsible for premature mortality. Drugs specifically approved by the FDA for SLE are limited to aspirin, corticosteroids, hydroxychloroquine and belimumab. Physicians commonly treat disease manifestations with immunosuppressive or corticosteroid therapies that have significant toxicities.

About Resunab

Resunab is a novel synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Pre-clinical and Phase 1 studies have shown Resunab to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in pre-clinical models of inflammation and fibrosis. Resunab is designed to trigger the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of pro-inflammatory eicosanoids and cytokines. Resunab has direct effects on fibroblasts to halt tissue scarring. In effect, Resunab triggers endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate, Resunab, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation, bacterial infections, and fibrotic processes. Resunab is currently in Phase 2 clinical studies for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis, skin-predominant dermatomyositis and systemic lupus erythematosus.

For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter , LinkedIn , Google+ and Facebook .

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact Jenene Thomas Jenene Thomas Communications, LLC Phone: +1 (908) 938-1475 Email: jenene@jenenethomascommunications.com Media Contact David Schull Russo Partners, LLC Phone: +1 (858) 717-2310 Email: david.schull@russopartnersllc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 55

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 0

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 159

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 197

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 115

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 175

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 0

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 148

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 11

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 72

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading

Top 5 Most Recently Viewed Articles

IASO Bio Achieves Major Milestone with Orphan Drug Status

Updated Category News Views 270

IASO Bio Earns Orphan Drug Designation for Breakthrough Therapy IASO Biotherapeutics, a key player in the biopharmaceutical sector, announced an exciting achievement as its groundbreaking treatment, Equecabtagene Autoleucel (Fucaso), received Orphan Drug Designation from the Ministry of Food and Drug Safety. This recognition is particularly significant for adults fighting...

Continue Reading
Transforming Experience: Honda Center's $1 Billion Revamp

Updated Category News Views 387

Transforming Experience: Honda Center's $1 Billion Revamp Honda Center Encore Is A Multi-Year Investment Led by the Samueli Family That Will Redefine the Arena Experience OC Sports & Entertainment (OCSE), connected with the operator of Honda Center, has announced a groundbreaking project known as Honda Center Encore. This ambitious venture involves a significant...

Continue Reading
PIMCO Municipal Income Fund Faces Market Pressures at New Lows

Updated Category News Views 192

PIMCO Municipal Income Fund's Recent Market Performance PIMCO Municipal Income Fund (PMF) has recently faced significant market challenges, as evidenced by its stock hitting a notable 52-week low at a price of $8.82. This decline isn't merely an isolated incident; it reflects ongoing pressures impacting the broader fixed-income sector. Investors are currently navigating...

Continue Reading
Exploring Non-Surgical Solutions for Prostate Health Issues

Updated Category News Views 174

Prostate health became a hot topic for many men over 50, especially with the rise of benign prostatic hyperplasia (BPH)—that uncomfortable enlargement that turns bathroom trips into sprints. Back then, treatment options were shaking up, and PAE was coming onto the scene like it owned the place. PAE vs. Traditional Surgery: The Fight for Relief In an era where...

Continue Reading
Applied Digital Appoints Laura Laltrello as COO for AI Growth

Updated Category News Views 245

Applied Digital Names Laura Laltrello as New COO Applied Digital Corporation (NASDAQ: APLD) is excited to announce the appointment of Laura Laltrello as its new Chief Operating Officer (COO). With an aim to strengthen the Company’s leadership in next-generation data centers and digital cloud solutions, Ms. Laltrello's role signifies a pivotal moment in the Company’s...

Continue Reading